For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Celgene Faces Biz Improvement Order over Delays in Side Effect Reporting
March 15, 2017
- Tokyo, Osaka Govts Issue Biz Improvement Order to Dealers over Fake Harvoni
March 14, 2017
- Orphan Status Withdrawn for 4 Flu Vaccines: MHLW Notification
March 13, 2017
- MHLW to Stockpile Enough Avigan for 30,000 Persons
March 13, 2017
- Drug Prices Should Be Raised for Products with Good Outcomes: Shiozaki
March 10, 2017
- Change Necessary for Ethical Drug Distribution Rules, Shiozaki Says after Fake Harvoni Fuss
March 10, 2017
- Reference Pricing on Agenda for CEFP Social Security Working Group
March 10, 2017
- NIBIOHN Looks to Spur Next-Gen Drug Development with Unique Antibody Techs, Joins Hands with 10 Companies
March 9, 2017
- MHLW to Set Up Panel on Drug Distribution after Fake Harvoni Flub, Eyes GDP Ordinance
March 8, 2017
- MHLW’s Guide to Recommend Against Prescribing Antibacterials for Colds, Diarrhea
March 8, 2017
- Tap Real-World Data for Optimal Use of High-Priced Meds: MHLW Bureau Chief
March 7, 2017
- 3 Kansai Medico Pharmacies Slapped with Biz Improvement Order over Fake Harvoni
March 7, 2017
- MHLW to Update Its Generic Roadmap in Line with Govt Target: Official
March 7, 2017
- PMDA Certified as APEC’s Training Center of Excellence for Regulatory Science
March 6, 2017
- Official Raw Plasma Prices for FY2017 Virtually Flat: MHLW Panel
March 6, 2017
- Panel OKs Orphan Designations for Olaparib, Inotuzumab Ozogamicin
March 6, 2017
- Opdivo Approval for Head and Neck Cancer Expected in Late March-Early April
March 6, 2017
- MHLW Advisory Committee OKs Ninlaro, Sovaldi for Genotypes 3-6
March 6, 2017
- MHLW OKs Add’l Indications for Revlimid, Other Drugs
March 3, 2017
- Orphan Status Dropped for 3 Drugs, Designation Given to Canakinumab
March 3, 2017
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…